Mind Medicine (also known as MindMed) was the primary psychedelic drugmaker to conduct an preliminary public providing (IPO), on Canada’s NEO Exchange in March 2020. The company had been based lower than a 12 months earlier, in May 2019. The drugmaker is at present conducting two part three studies evaluating COMP360 in treatment-resistant depression. Result...